If you’ve seen a headline about “oral ketamine for depression, minus the trip,” it’s worth understanding exactly what the research says before you draw conclusions from it. The story is genuinely interesting, and it’s also more mixed than a quick skim suggests.
Here’s the honest version, along with what it does and doesn’t change for someone considering ketamine therapy today.
What the Studies Tested
The drug in question is KET01, a prolonged-release tablet of ketamine developed to release the medicine slowly over hours rather than all at once. Researchers published two studies together in JAMA Network Open: a phase 1 crossover trial focused on dissociation, and a phase 2 placebo-controlled trial in 122 outpatients with treatment-resistant depression.
The core idea is straightforward. Ketamine’s dissociative effects—the dreamy, detached state people describe during an infusion—are driven largely by how high and how fast the drug peaks in the bloodstream. A slow-release tablet keeps blood levels low and gradual, which should, in theory, deliver the antidepressant benefit while sidestepping the dissociation. That’s the premise these trials set out to test.
The Tolerability Result Was Striking
On that front, the tablet did what it was designed to do. In the dissociation study, a single dose of KET01 produced essentially no dissociative effects. The contrast with the active comparator was stark: about 96% of people on intranasal esketamine experienced dissociation, versus roughly 4% on KET01. The tablet also avoided the meaningful blood-pressure bumps that come with faster-acting forms.
That matters for a real reason. The need to monitor dissociation and blood pressure is exactly why esketamine and IV ketamine are given in supervised clinical settings rather than at home. A version that reliably skips both would, in principle, be easier to deliver. So the tolerability signal is a legitimate advance worth paying attention to.
But the Main Efficacy Goal Was Missed
This is the part the cheerful headlines tend to soften. In the phase 2 trial, daily KET01 reduced depression severity more than placebo at day 4 and day 7—an encouraging early signal. By day 21, the study’s primary endpoint, the difference from placebo was no longer statistically significant.
A single dose caused almost no dissociation—a real tolerability win. But at the trial’s primary 21-day mark, the tablet did not clearly separate from placebo. Gentle is not the same as proven.
In plain terms: the tablet was easy to take and hinted at an early antidepressant effect, but it did not clearly prove a lasting advantage over a sugar pill at the point the researchers had defined as the real test. That doesn’t make it a failure—early-phase trials exist precisely to find these signals and limits—but it does mean the drug has more to prove.
It also raises a genuinely open scientific question: whether ketamine’s dissociative peak and its antidepressant effect can actually be separated, or whether that fast, high peak is part of how the benefit gets delivered. Researchers don’t fully know yet. We’ve written before about what dissociation during ketamine actually is, and why it may be more than just a side effect.
What This Does—and Doesn’t—Change Right Now
A few practical takeaways if you’re someone weighing treatment, not reading this out of curiosity.
- You can’t get KET01 today. It’s investigational. There’s no approval, no prescribing, and no announced timeline. Promising research is not the same as an available treatment.
- Oral ketamine already exists in other forms. Some clinics use compounded oral or sublingual ketamine now, but that’s a different product from the prolonged-release tablet, with its own evidence and limitations. We compare the routes in oral vs IV ketamine.
- IV ketamine still has the deepest track record. For treatment-resistant depression, monitored IV infusions have years of evidence behind their rapid effect—the kind of durable, replicated benefit KET01 hasn’t yet shown.
If you’ve been hoping a no-dissociation pill is around the corner, we understand the appeal, and we don’t blame anyone for wanting to skip the strange part. But betting your relief on an unapproved drug that didn’t clear its own primary endpoint is a real trade-off, especially if you’re struggling now.
On the Fear of Dissociation Itself
A lot of interest in a “trip-free” ketamine comes from worry about the dissociative experience. That worry is worth addressing directly, because it’s often based on the idea that dissociation is dangerous or something to endure rather than something that’s managed.
In a monitored setting, dissociation is temporary, expected, and closely attended. It builds as the infusion runs and fades as it ends. Many people find it neutral; some find it genuinely meaningful; a few find it uncomfortable, which is exactly why we prepare you for it and stay present throughout. If intensity is your concern, we address it plainly in what if the experience feels too intense and managing anxiety during a session. Marla, our CRNA founder, is in the room the whole time, and our therapy dogs, Walter White and Wilma, are part of why the space feels calm rather than clinical. You can read what the experience is actually like in what a ketamine infusion feels like.
None of that is a knock on the research. A gentler oral option could genuinely help people who can’t tolerate other forms, and we’ll be glad if a future version of KET01 earns its place. We’re simply making sure the current state of the evidence is described accurately, not oversold.
The Honest Bottom Line
The 2026 oral prolonged-release ketamine trials are a real step in a worthwhile direction: a formulation that largely avoids dissociation and blood-pressure effects, which could eventually make treatment simpler to deliver. But it missed its main 21-day efficacy goal, it’s still investigational, and it leaves open the deep question of whether you can remove the “trip” without removing part of the benefit. For now, if you’re living with depression that hasn’t responded to other treatments, the proven, available path is supervised care with a track record—and we’re happy to walk through what that would look like for you, headlines and all.